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Practice
Statistics in practice
The simplest statistical test: how to check for a difference
between treatments
Stuart J Pocock
The complexity of statistical methods for analysing clini-
cal data can make interpreting clinical trial reports a
daunting task for many readers. However, the key result
of many trials could be presented and interpreted using
quite basic statistical methods. The overall spirit of this
article is to encourage all interested in understanding
clinical trials to “feel the data” rather than get too
absorbed in the technicalities (and occasional confu-
sions) of advanced statistical techniques.
For many trials the primary outcome is a disease
event. This might be death or a composite outcome such
as death, myocardial infarction, or stroke. The standard
statistical methods—Cox proportional hazard models
and log rank tests—take account of variation in patient
follow-up times, but the consequent hazard ratios, confi-
dence intervals, and P values seem a mysterious “black
box” to some readers. Alternatively, if events relate to a
fixed follow-up time then methods for comparing two
proportions (for example, the 2 test) may be used.
This article describes a much easier method than
these, which readers can use to assess quickly the
strength of evidence for a treatment difference in an
event outcome. It’s surprising even how many
statisticians don’t know this simplest test: I first heard of
it from a cardiologist.
The simplest test
Consider a randomised clinical trial with two treatment
groups of roughly equal size. Let the outcome of inter-
est be a clinical event.
The key data are the numbers of patients
experiencing the event by treatment group. The figure
shows how to perform a statistical test of significance
based solely on these two numbers.
Calculate the difference in the two numbers of
events and divide by the square root of their sum. Call
the resulting number z. Under the null hypothesis that
the two treatments have identical influence on the risk
of an event, z is approximately a standardised normal
deviate—that is, it has a normal distribution with mean
0 and variance 1. From commonly available normal
distribution tables, z can be converted into a P value
(see figure). For instance z > 1.96 means P < 0.05 and
z > 2.58 means P < 0.01.
This test is approximate but generally gives reliable
results for the following reason. With randomisation,
the number of patients in the two treatment groups will
be almost equal, as will be the length of patient follow-
up. Event rates are usually quite low—for example, less
than 20% of patients (and often much lower)—and so
the number of patients having an event in each group
can be considered to have Poisson distribution.
Provided that the total number of events is not too
small—for example, not less than 20, then the normal
approximation for the comparison of two Poisson
random variables1 leads to the formula in the figure.
It takes about 15 seconds to do this test on a calcu-
lator, which makes it a useful way of comparing event
counts in a trial with equal randomisation. Note that it
ignores the numbers randomised and the follow-up
times, except to assume they are virtually equal.
The key information lies in the numerators—the
numbers with an event—the size of the denominators
being unimportant. For instance, if a trial had twice the
number of patients (at lower risk) while still having the
same numbers of events, the amount of information
would be essentially the same. However, doubling the
number of events hugely affects a trial’s statistical power.
This technique has two limitations. Firstly, if the
denominators differ by a non-negligible amount then
the test will become biased in the obvious direction.
Secondly, if event rates are high the test becomes
conservative—that is, P values are larger than they
should be. However, for most published trials these
potential limitations seem negligible.
This simple test gives an instant feel of the strength
of evidence for a treatment difference. However, in any
trial publication it should not replace the more
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• Consider a clinical trial with equal randomisation
• Number of events in the two treatments groups are a and b respectively
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conventional statistical tests, such as a log rank test or
(if length of follow-up is fixed) a 2 test.
In estimating the magnitude of treatment effect, the
relative risk or hazard ratio is usually presented. This is
approximately equal to the ratio of the numbers of
patients with an event.
Examples using the test
This simple test is now applied to some recent trials
(see table). The VIGOR trial reported an excess risk of
serious thrombotic cardiovascular events in patients
taking rofecoxib compared with those taking naproxen
(hazard ratio 2.37, 95% confidence interval 1.39 to
4.00).2 Unfortunately, the numbers of patients experi-
encing such events—45 and 19 respectively in the
rofexocib and naproxen groups3—were not presented
in the original publication. On the basis of the formula
in the figure, z = (45 − 19)/√45+19= 3.25, which gives
P = 0.0012, which reveals that the treatment difference
is very highly significant. This has been subsequently
confirmed by a log rank test (P = 0.0016). Note the
ratio of events 45/19 = 2.37 is here the same as the
hazard ratio.
Data monitoring in the MOXCON trial,4 moxoni-
dine versus placebo in heart failure, focused on all
cause mortality. An interim analysis, with 1860 patients
randomised, found 46 and 25 deaths in the
moxonidine and placebo groups respectively. The cal-
culation reveals that z = (46 − 25)/√46+25= 2.49, thus
P = 0.013, strong evidence of excess mortality for
moxonidine. This key information led to the trial being
stopped early. With 73 more patients randomised and
15 more deaths, the final data had 54 versus 32 deaths
in moxonidine and placebo groups respectively, log
rank P = 0.012. At interim analyses, a reliable log rank
test is often impossible as for some patients the “last
date known alive” is unknown. This simple test is there-
fore particularly valuable in data monitoring.
This test is also useful in clarifying why different
end points in a trial give apparently inconsistent
results. In the PROactive trial5 in 5238 diabetic patients
the primary end point (a composite of cardiovascular
events) occurred in 514 and 572 patients in the piogli-
tazone and placebo groups respectively. This difference
of 58 events gives z = 1.76 and hence P = 0.078, similar
to the published log rank P = 0.095. The authors
focused on the main composite secondary end point
(death, myocardial infarction, and stroke) affecting 301
and 358 patients in pioglitazone and placebo groups
respectively. This difference of 57 events (one fewer
than for the primary end point but based on fewer
events) has z = 2.22 and P = 0.026, similar to the
published log rank P = 0.027. Perhaps the primary end
point was “handicapped” into non-significance by
including other cardiovascular events that contributed
no extra treatment difference. The similarity of
findings for the primary and main secondary end
points helps to emphasise that P = 0.095 and P = 0.027
are not far apart in their interpretation. It is sad that
achieving P < 0.05 carries such unreasonable weight in
considering whether a treatment is effective. Both
analyses provide modest, but inconclusive, evidence
favouring pioglitazone, but the article’s post hoc
emphasis on the secondary end point merits caution.
Note that the ratios of events (514/572 = 0.90 and
301/358 = 0.84) for the primary and main secondary
end point respectively are the same as the hazard ratios
using Cox models—that is, simple division achieves the
same as more complex modelling.
The simple test is also relevant to meta-analyses,
provided that all included trials have equal randomisa-
tion. A recent meta-analysis studied the incidence of
target lesion revascularisation in six trials comparing
paclitaxel-eluting and sirolimus-eluting stents.6
Crudely combining the data on 3669 patients in all six
trials, target lesion revascularisation was done in
95 and 142 patients respectively in the sirolimus
and paclitaxel groups. Hence z = (142 − 95)/
√142+95= 3.05, giving P = 0.002. This instant guide to
a treatment difference is backed up by the published
stratified Mantel-Haenszel test (P = 0.001). It is pleasing
to see that by ignoring the denominators and pooling
the data from all trials, the simple test still gave the
“right” answer.
The simplest test can also help interpret claims
about treatment breakthroughs in the lay press. For
instance, the Guardian’s lead article on 10 December
20057 had the headline “New cancer drugs put NHS
under pressure” and concluded that “pooled results
from three European trials of anastrozole (involving
over 4000 women) suggested that post-menopausal
women who switched from tamoxifen two years after
surgery were more likely to be alive two and a half
years later. There were 29% fewer deaths among
patient who changed.” Unusually (and commendably)
this article gave the actual numbers of deaths: 66 in
those who switched to anastrozole compared with 90
in those continuing to take tamoxifen. Our quick test
gives z = (90 − 66)/√90+66= 1.92 and hence P = 0.06.
Examples of randomised trial results analysed using the simplest statistical test
Trial (treatment
comparison) Endpoint No of events Difference
Square root of
sum of events z
Consequent
P value
Published
P value
VIGOR (rofecoxib v
naproxen)2
Serious thrombotic
cardiovascular events
45 v 19 26 8 3.25 0.0012 0.0016
MOXCON (moxonidine v
placebo)3
All cause death when trial
was stopped
46 v 25 21 8.43 2.49 0.013 0.012*
PROactive Composite primary
endpoint†
514 v 572 58 32.95 1.76 0.078 0.095
Death, myocardial
infarction, or stroke
301 v 358 57 25.67 2.22 0.026 0.027
Meta-analysis
(sirolimus-eluting v
paclitaxel-eluting stent)5
Target lesion
revascularisation
95 v 142 47 15.40 3.05 0.002 0.001
*Published P value in MOXCON based on an additional 15 deaths.
†The composite primary end point included death, myocardial infarction, stroke, acute coronary syndrome, endovascular surgical intervention in coronary or leg
arteries, and amputation above the ankle.
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Thus, Guardian readers can assess for themselves that
this is encouraging but not conclusive evidence of
anastrozole’s superiority, which helps tone down the
article’s extravagant assertions.
The value of simplicity
Although many sophisticated, complex statistical
methods are appropriately used in analysing medical
data, it is important to identify the key information that
drives a study’s conclusions. In randomised trials with
an event outcome, what matters most are the numbers
of patients in each treatment group experiencing the
event. The simple test described here uses those data
alone and gives quick, reliable insight into a trial’s core
message.
This test assumes that the numbers of events in
each group are Poisson variables. Under the null
hypothesis, this means that the proportion of the total
events in one group is a binomial random variable with
probability 12. This and its normal approximation is
widely known as McNemar’s test.1 8 However, few texts1
and indeed few statisticians and medical researchers
realise how that test tackles the issue described and is
most easily calculated by the formula in the figure.
The test is also useful when inspecting multiple
outcomes in a trial—for example, data monitoring
committees looking at tables of frequency of serious
adverse events by treatment. Rather than calculating P
values for every event, they can use the test to identify
any interesting numerical differences of potential con-
cern. Although there is an increased risk of “false posi-
tives” when studying multiple outcomes, the simple test
plus any z score above 2 suggests the difference may
not be due to chance.
For clinical trials with equal randomisation and
event outcomes this simple test helps put readers in
better touch with the key findings. Of course, a more
exact test (such as logrank) should be done, but by then
the simple test has already given the game away.
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Summary points
Many clinical trials have two treatment groups,
equal randomisation, and an event outcome
The key data are the numbers of patients with the
event in each group
The simplest statistical test compares these two
numbers
It is a useful, quick, and reliable guide to assessing
evidence for a treatment difference
It is one example of how authors and readers
need to get a “feel for data” by means of simple,
clear statistics
A memorable patient
Ben
Ben was one of those delightful patients who put up with much
but never complained. He had his first heart attack in 1975, but
his real claim to fame was in 1985 when he appeared in a
cardiology textbook. Seated at a Guy’s Hospital lipid clinic, aged
63, he faced the camera to show his xanthelasma and his blood
pressure being measured, while continuing to smoke his cigarette.
As time went by, he and I enjoyed that subtle transition, for
which general practice still remains the richer, from
doctor-patient to professional friendship. Last winter, I was
tidying the office before we moved to a new health centre, and I
came across the textbook. I managed to persuade Ben to pose for
my mobile telephone camera, as he waited for his bus home from
the surgery, holding the book open at the appropriate page. With
his permission, and the new technology, the pictures were
emailed to the author, now a professor of cardiology.
At 84, however, Ben found life getting tougher; he developed
heart failure. After emerging from a 10 day inpatient stay minus
warfarin and with a better dose of digoxin, he was due to come to
me a week later for review. In the event, I was called directly to the
car park: after a good breakfast, Ben had got in the car with his
wife and son, but shortly into the journey he had complained of
central chest pain and lost consciousness. When I saw him it was
clear that his intermittent peaceful respiration would soon cease.
“I don’t think we are going to do anything are we?” I asked his
wife and son. We knew each other, and they agreed calmly just to
wait.
Within five minutes, a peaceful end came, but what to do next?
I got into his car, and we all drove to the undertaker. We agreed
there was much in this which would have appealed to Ben’s sense
of humour. His son and I laid him out before I returned, only 20
minutes late, for the rest of the surgery.
His death rekindled for me the sense of privilege that comes
with continuity of care. I am not sure that this is measurable or
worthy of “points” on a so called quality scale, or for how much
longer we in general practice may enjoy it.
John S N Anderson general practitioner,Woodlands Health Centre,
Paddock Wood, Tonbridge (dr_nick@talk21.com)
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